Endoxifen (BioDeep_00001874581)
Main id: BioDeep_00000011255
代谢物信息卡片
4-Hydroxy-N-desmethyltamoxifen
化学式: C25H27NO2 (373.2041682)
中文名称: (Z)-4-羟基-N-去甲基他莫昔芬(异构体的混合物), N-去甲基-4-羟基-
谱图信息:
最多检出来源 Viridiplantae(plant) 16.67%
分子结构信息
SMILES: CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCNC)C3=CC=CC=C3
InChI: InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:80555
- KEGG: C16547
- PubChem: 10090750
- ChEMBL: CHEMBL1093458
- CAS: 110025-28-0
- CAS: 112093-28-4
- PubChem: 51090876
- PDB-CCD: 9XY
- NIKKAJI: J393.650C
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jing Zhao, Dongming Yan, Yue Li, Xiaoqing Xu, Fengling Li, Shuang Zhang, Jingyi Jin, Furong Qiu. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2024 Apr; 1237(?):124100. doi:
10.1016/j.jchromb.2024.124100. [PMID: 38547701] - Magnus Bäcklund, Mikael Eriksson, Marike Gabrielson, Mattias Hammarström, Steve Quay, Jenny Bergqvist, Roxanna Hellgren, Kamila Czene, Per Hall. Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial.
The oncologist.
2022 Jul; 27(7):e597-e600. doi:
10.1093/oncolo/oyac102. [PMID: 35604960] - Stefan Rehnmark, Ivan Shabo, Håkan Randahl, Yvonne Wengström, Per Rydberg, Elham Hedayati. Preliminary results using a kit to measure tamoxifen and metabolites concentrations in capillary blood samples from women with breast cancer.
Scientific reports.
2022 01; 12(1):1643. doi:
10.1038/s41598-022-05443-0. [PMID: 35102224] - Maria Lucia Souza Siqueira, Sara Michelli Vieira Andrade, José Luiz Fernandes Vieira, Marta Chagas Monteiro. A preliminary study on the association of tamoxifen, endoxifen, and 4-hydroxytamoxifen with blood lipids in patients with breast cancer.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2021 Oct; 142(?):111972. doi:
10.1016/j.biopha.2021.111972. [PMID: 34391185] - Alicja Puszkiel, Cécile Arellano, Christelle Vachoux, Alexandre Evrard, Valérie Le Morvan, Jean-Christophe Boyer, Jacques Robert, Caroline Delmas, Florence Dalenc, Marc Debled, Laurence Venat-Bouvet, William Jacot, Nadine Dohollou, Chantal Bernard-Marty, Hortense Laharie-Mineur, Thomas Filleron, Henri Roché, Etienne Chatelut, Fabienne Thomas, Melanie White-Koning. Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.
Clinical pharmacology and therapeutics.
2021 05; 109(5):1244-1255. doi:
10.1002/cpt.2077. [PMID: 33047329] - Linda Thorén, Jonatan D Lindh, Gerd Ackehed, Marianne Kristiansen Kringen, Per Hall, Jonas Bergh, Espen Molden, Sara Margolin, Erik Eliasson. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
British journal of clinical pharmacology.
2021 03; 87(3):1243-1252. doi:
10.1111/bcp.14500. [PMID: 32713032] - C Louwrens Braal, Koen G A M Hussaarts, Lieke Seuren, Esther Oomen-de Hoop, Peter de Bruijn, Stefan A J Buck, Monique E M M Bos, Martine F Thijs-Visser, Hanneke J M Zuetenhorst, Daniëlle Mathijssen-van Stein, Mijntje B Vastbinder, Roelof W F van Leeuwen, Teun van Gelder, Stijn L W Koolen, Agnes Jager, Ron H J Mathijssen. Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
Breast cancer research and treatment.
2020 Nov; 184(1):107-113. doi:
10.1007/s10549-020-05829-6. [PMID: 32803636] - Milena Gusella, Felice Pasini, Barbara Corso, Laura Bertolaso, Giovanni De Rosa, Cristina Falci, Yasmina Modena, Carmen Barile, Donatella Da Corte Z, AnnaPaola Fraccon, Silvia Toso, Elisabetta Cretella, Antonella Brunello, Caterina Modonesi, Romana Segati, Cristina Oliani, Nadia Minicuci, Roberto Padrini. Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?.
Pharmacology research & perspectives.
2020 10; 8(5):e00646. doi:
10.1002/prp2.646. [PMID: 32813313] - Anna Mueller-Schoell, Lena Klopp-Schulze, Werner Schroth, Thomas Mürdter, Robin Michelet, Hiltrud Brauch, Wilhelm Huisinga, Markus Joerger, Patrick Neven, Stijn L W Koolen, Ron H J Mathijssen, Ellen Copson, Diana Eccles, Sylvia Chen, Balram Chowbay, Arafat Tfayli, Nathalie K Zgheib, Matthias Schwab, Charlotte Kloft. Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach.
Clinical pharmacology and therapeutics.
2020 09; 108(3):661-670. doi:
10.1002/cpt.1960. [PMID: 32578187] - Rangel-Méndez Jorge-Aarón, Rubi-Castellanos Rodrigo, Moo-Puc Rosa Esther. Endoxifen levels and metabolic phenotype-associated factors in Mexican Mestizo patients under tamoxifen treatment.
Pharmacogenomics.
2020 08; 21(13):929-943. doi:
10.2217/pgs-2020-0061. [PMID: 32808577] - Anabel Beatriz Sanchez-Spitman, Dirk-Jan A R Moes, Jesse J Swen, Vincent O Dezentjé, Diether Lambrechts, Patrick Neven, Hans Gelderblom, Henk-Jan Guchelaar. Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.
Cancer chemotherapy and pharmacology.
2020 06; 85(6):1141-1152. doi:
10.1007/s00280-020-04089-x. [PMID: 32468081] - Marina Ariño Martin, Jayaraman Sivaguru, John McEvoy, Prinpida Sonthiphand, Andre Delorme, Eakalak Khan. Photodegradation of (E)- and (Z)-Endoxifen in water by ultraviolet light: Efficiency, kinetics, by-products, and toxicity assessment.
Water research.
2020 Mar; 171(?):115451. doi:
10.1016/j.watres.2019.115451. [PMID: 31901682] - Jeanine Marie Nardin, Werner Schroth, Thais Abreu Almeida, Thomas Mürdter, Solane Picolotto, Evelyn Castillo Lima Vendramini, Reiner Hoppe, Jenifer Primon Kogin, Diandra Miqueleto, Silvia Dark Robaskievicz de Moraes, Matthias Schwab, Roberto Flavio Pecoits-Filho, Hiltrud Brauch, José Claudio Casali-da-Rocha. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Clinical and translational science.
2020 03; 13(2):284-292. doi:
10.1111/cts.12707. [PMID: 31573754] - João Paulo Bianchi Ximenez, Jurandyr Moreira de Andrade, Maria Paula Marques, Eduardo Barbosa Coelho, Guilherme Suarez-Kurtz, Vera Lucia Lanchote. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
BMC pharmacology & toxicology.
2019 12; 20(Suppl 1):81. doi:
10.1186/s40360-019-0358-y. [PMID: 31852530] - Ta-Chung Chao, Wen-Chi Pan, Yi-Fang Tsai, Yueh-Ching Chou, Yu-Rong Liu, Sheng-Fan Wang, Ying-Jen Chen, Pavel Souček, Yune-Fang Ueng. Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol.
Toxicology and applied pharmacology.
2019 09; 378(?):114619. doi:
10.1016/j.taap.2019.114619. [PMID: 31195002] - Alicja Puszkiel, Cécile Arellano, Christelle Vachoux, Alexandre Evrard, Valérie Le Morvan, Jean-Christophe Boyer, Jacques Robert, Caroline Delmas, Florence Dalenc, Marc Debled, Laurence Venat-Bouvet, William Jacot, Etienne Suc, Isabelle Sillet-Bach, Thomas Filleron, Henri Roché, Etienne Chatelut, Melanie White-Koning, Fabienne Thomas. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.
Clinical pharmacology and therapeutics.
2019 09; 106(3):585-595. doi:
10.1002/cpt.1404. [PMID: 30786012] - M van Nuland, N Venekamp, N de Vries, K A M de Jong, H Rosing, J H Beijnen. Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Feb; 1106-1107(?):26-34. doi:
10.1016/j.jchromb.2019.01.001. [PMID: 30639947] - U Weissenstein, M Kunz, M Oufir, J T Wang, M Hamburger, K Urech, U Regueiro, S Baumgartner. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro.
BMC complementary and alternative medicine.
2019 Jan; 19(1):23. doi:
10.1186/s12906-019-2439-2. [PMID: 30658716] - Yenny, Sonar S Panigoro, Denni J Purwanto, Adi Hidayat, Melva Louisa, Rizka Andalusia, Rianto Setiabudy. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
Endocrine, metabolic & immune disorders drug targets.
2019; 19(8):1198-1206. doi:
10.2174/1871530319666190306094617. [PMID: 30843495] - Laura E Jansen, Wendy A Teft, Rhiannon V Rose, Daniel J Lizotte, Richard B Kim. CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.
Breast cancer research and treatment.
2018 Oct; 171(3):701-708. doi:
10.1007/s10549-018-4876-x. [PMID: 29980881] - Shreya Tocaciu, Lesley J Oliver, Ray M Lowenthal, Gregory M Peterson, Rahul Patel, Madhur Shastri, Georgia McGuinness, Inger Olesen, J Helen Fitton. The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer.
Integrative cancer therapies.
2018 03; 17(1):99-105. doi:
10.1177/1534735416684014. [PMID: 28008779] - Thomas Helland, Nina Henne, Ersilia Bifulco, Bjørn Naume, Elin Borgen, Vessela N Kristensen, Jan T Kvaløy, Timothy L Lash, Grethe I G Alnæs, Ron H van Schaik, Emiel A M Janssen, Steinar Hustad, Ernst A Lien, Gunnar Mellgren, Håvard Søiland. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
Breast cancer research : BCR.
2017 Nov; 19(1):125. doi:
10.1186/s13058-017-0916-4. [PMID: 29183390] - Sven de Krou, Hilde Rosing, Bastiaan Nuijen, Jan H M Schellens, Jos H Beijnen. Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.
Therapeutic drug monitoring.
2017 04; 39(2):132-137. doi:
10.1097/ftd.0000000000000372. [PMID: 28045782] - Shengyue Yuan, Qingrong Sun, Yao Chen, Jun Liao. A Pharmacokinetic-Pharmacodynamic Model of Tamoxifen and Endoxifen to Predict Their Distribution and Effects on Inhibition of Tumor Growth.
Drug metabolism letters.
2017; 11(2):93-101. doi:
10.2174/1872312811666170815160751. [PMID: 28814243] - Natalia Sutiman, Joanne Siok Liu Lim, Thomas E Muerdter, Onkar Singh, Yin Bun Cheung, Raymond Chee Hui Ng, Yoon Sim Yap, Nan Soon Wong, Peter Cher Siang Ang, Rebecca Dent, Werner Schroth, Matthias Schwab, Chiea Chuen Khor, Balram Chowbay. Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
Clinical pharmacokinetics.
2016 10; 55(10):1239-1250. doi:
10.1007/s40262-016-0402-7. [PMID: 27098059] - Wei Xiong, Jia-jia Zhao, Ling Wang, Xue-hua Jiang, Xiao-qiu Tao. [Advances in the research of pharmacogenomics of tamoxifen].
Yao xue xue bao = Acta pharmaceutica Sinica.
2016 09; 51(9):1356-67. doi:
. [PMID: 29924509] - Sara L Henderson, Wendy A Teft, Richard B Kim. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.
BMC cancer.
2016 05; 16(?):304. doi:
10.1186/s12885-016-2342-x. [PMID: 27169677] - Marina V Antunes, Tatiana Aparecida da Fontoura Timm, Vanessa de Oliveira, Dilana E Staudt, Suziane Raymundo, Gustavo Gössling, Jorge V Biazús, José A Cavalheiro, Daniela D Rosa, Pierre Wallemacq, Vincent Haufroid, Rafael Linden, Gilberto Schwartsmann. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
Therapeutic drug monitoring.
2015 Dec; 37(6):733-44. doi:
10.1097/ftd.0000000000000212. [PMID: 25853922] - Oukseub Lee, David Ivancic, Subhashini Allu, Ali Shidfar, Kara Kenney, Irene Helenowski, Megan E Sullivan, Miguel Muzzio, Denise Scholtens, Robert T Chatterton, Kevin P Bethke, Nora M Hansen, Seema A Khan. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
Cancer chemotherapy and pharmacology.
2015 Dec; 76(6):1235-46. doi:
10.1007/s00280-015-2848-y. [PMID: 26560487] - Noelia Negreira, Jorge Regueiro, Miren López de Alda, Damià Barceló. Transformation of tamoxifen and its major metabolites during water chlorination: Identification and in silico toxicity assessment of their disinfection byproducts.
Water research.
2015 Nov; 85(?):199-207. doi:
10.1016/j.watres.2015.08.036. [PMID: 26320721] - V O Dezentjé, F L Opdam, H Gelderblom, J Hartigh den, T Van der Straaten, R Vree, E Maartense, C H Smorenburg, H Putter, A S Dieudonné, P Neven, C J H Van de Velde, J W R Nortier, H-J Guchelaar. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Breast cancer research and treatment.
2015 Oct; 153(3):583-90. doi:
10.1007/s10549-015-3562-5. [PMID: 26369533] - Miyuki Watanabe, Noriko Watanabe, Sakiko Maruyama, Takashi Kawashiro. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.
Drug metabolism and pharmacokinetics.
2015 Oct; 30(5):325-33. doi:
10.1016/j.dmpk.2015.05.004. [PMID: 26423799] - Marieke E B Welzen, Vincent O Dezentjé, Ron H N van Schaik, Angela P H Colbers, Henk-Jan Guchelaar, Nielka P van Erp, Jan den Hartigh, David M Burger, Hanneke W M van Laarhoven. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.
Therapeutic drug monitoring.
2015 Aug; 37(4):501-7. doi:
10.1097/ftd.0000000000000195. [PMID: 26192892] - Ewa E Hennig, Magdalena Piatkowska, Jakub Karczmarski, Krzysztof Goryca, Elzbieta Brewczynska, Radoslaw Jazwiec, Anna Kluska, Robert Omiotek, Agnieszka Paziewska, Michal Dadlez, Jerzy Ostrowski. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
BMC cancer.
2015 Aug; 15(?):570. doi:
10.1186/s12885-015-1575-4. [PMID: 26232141] - Ying Hui, Lijun Luo, Lingtian Zhang, Katsuhisa Kurogi, Chunyang Zhou, Yoichi Sakakibara, Masahito Suiko, Ming-Cheh Liu. Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis.
Journal of pharmacological sciences.
2015 Jul; 128(3):144-9. doi:
10.1016/j.jphs.2015.06.004. [PMID: 26169578] - Changde Zhang, Qiu Zhong, Qiang Zhang, Shilong Zheng, Lucio Miele, Guangdi Wang. Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.
Breast cancer research and treatment.
2015 Jul; 152(2):283-91. doi:
10.1007/s10549-015-3461-9. [PMID: 26071758] - Yun Ju Chae, Keon Jin Lee, Hong Joon Lee, Ki-Wug Sung, Jin-Sung Choi, Eun Hui Lee, Sang June Hahn. Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels.
European journal of pharmacology.
2015 Apr; 752(?):1-7. doi:
10.1016/j.ejphar.2015.01.048. [PMID: 25680947] - Juan Peris-Vicente, Enrique Ochoa-Aranda, Devasish Bose, Josep Esteve-Romero. Determination of tamoxifen and its main metabolites in plasma samples from breast cancer patients by micellar liquid chromatography.
Talanta.
2015 Jan; 131(?):535-40. doi:
10.1016/j.talanta.2014.07.093. [PMID: 25281137] - Marina Venzon Antunes, Suziane Raymundo, Vanessa de Oliveira, Dilana Elisabeth Staudt, Gustavo Gössling, Giovana Piva Peteffi, Jorge Villanova Biazús, José Antônio Cavalheiro, Marie Tre-Hardy, Arnaud Capron, Vincent Haufroid, Pierre Wallemacq, Gilberto Schwartsmann, Rafael Linden. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy.
Talanta.
2015 Jan; 132(?):775-84. doi:
10.1016/j.talanta.2014.10.040. [PMID: 25476377] - Karen M Schweikart, Sandy R Eldridge, Stephanie L Safgren, Toufan Parman, Joel M Reid, Matthew M Ames, Matthew P Goetz, Myrtle A Davis. Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats.
Toxicologic pathology.
2014 Dec; 42(8):1188-96. doi:
10.1177/0192623314525688. [PMID: 24670817] - Joel M Reid, Matthew P Goetz, Sarah A Buhrow, Chad Walden, Stephanie L Safgren, Mary J Kuffel, Kathryn E Reinicke, Vera Suman, Paul Haluska, Xiaonan Hou, Matthew M Ames. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies.
Cancer chemotherapy and pharmacology.
2014 Dec; 74(6):1271-8. doi:
10.1007/s00280-014-2605-7. [PMID: 25318936] - Philipp Y Maximov, Russell E McDaniel, Daphne J Fernandes, Valeriy R Korostyshevskiy, Puspanjali Bhatta, Thomas E Mürdter, David A Flockhart, V Craig Jordan. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
British journal of pharmacology.
2014 Dec; 171(24):5624-35. doi:
10.1111/bph.12864. [PMID: 25073551] - Cécile Arellano, Ben Allal, Anwar Goubaa, Henri Roché, Etienne Chatelut. An UPLC-MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers.
Journal of pharmaceutical and biomedical analysis.
2014 Nov; 100(?):254-261. doi:
10.1016/j.jpba.2014.07.033. [PMID: 25173109] - Eduardo Martinez de Dueñas, Enrique Ochoa Aranda, Isabel Blancas Lopez-Barajas, Teresa Ferrer Magdalena, Fernando Bandrés Moya, Luis Miguel Chicharro García, José A Gómez Capilla, Mercedes Zafra Ceres, Tomás de Haro, Regina Romero Llorens, Carlos Ferrer Albiach, Rafael Ferriols Lisart, Dolores Chover Lara, Angela López Rodríguez, Javier Munárriz Ferrandis, Santiago Olmos Antón. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Breast (Edinburgh, Scotland).
2014 Aug; 23(4):400-6. doi:
10.1016/j.breast.2014.02.008. [PMID: 24685597] - N G L Jager, H Rosing, J H M Schellens, J H Beijnen, S C Linn. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.
Breast cancer research and treatment.
2014 Jul; 146(1):137-44. doi:
10.1007/s10549-014-2999-2. [PMID: 24859000] - Steven E Gryn, Wendy A Teft, Richard B Kim. Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort.
Pharmacogenetics and genomics.
2014 Jul; 24(7):367-9. doi:
10.1097/fpc.0000000000000051. [PMID: 24915025] - Philipp Y Maximov, Daphne J Fernandes, Russell E McDaniel, Cynthia B Myers, Ramona F Curpan, V Craig Jordan. Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
Journal of medicinal chemistry.
2014 Jun; 57(11):4569-83. doi:
10.1021/jm500569h. [PMID: 24805199] - N G L Jager, H Rosing, J H M Schellens, S C Linn, J H Beijnen. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care.
Breast cancer research and treatment.
2014 Feb; 143(3):477-83. doi:
10.1007/s10549-013-2826-1. [PMID: 24390246] - Anne Gingery, Malayannan Subramaniam, Kevin S Pitel, Jordan M Reese, Muzaffer Cicek, Laurence B Lindenmaier, James N Ingle, Matthew P Goetz, Russell T Turner, Urszula T Iwaniec, Thomas C Spelsberg, John R Hawse. The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton.
PloS one.
2014; 9(5):e98219. doi:
10.1371/journal.pone.0098219. [PMID: 24853369] - Kathryn J Ruddy, Stephen D Desantis, Rebecca S Gelman, Alan H B Wu, Rinaa S Punglia, Erica L Mayer, Sara M Tolaney, Eric P Winer, Ann H Partridge, Harold J Burstein. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Breast cancer research and treatment.
2013 Oct; 141(3):421-7. doi:
10.1007/s10549-013-2700-1. [PMID: 24062210] - Ernst A Lien, Håvard Søiland, Steinar Lundgren, Turid Aas, Vidar M Steen, Gunnar Mellgren, Jennifer Gjerde. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.
Breast cancer research and treatment.
2013 Sep; 141(2):243-8. doi:
10.1007/s10549-013-2677-9. [PMID: 23996142] - Wei Lv, Jinzhong Liu, Deshun Lu, David A Flockhart, Mark Cushman. Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.
Journal of medicinal chemistry.
2013 Jun; 56(11):4611-8. doi:
10.1021/jm400364h. [PMID: 23731360] - Kazuma Kiyotani, Taisei Mushiroda, Hitoshi Zembutsu, Yusuke Nakamura. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.
Journal of human genetics.
2013 Jun; 58(6):327-33. doi:
10.1038/jhg.2013.39. [PMID: 23657426] - Inna Y Gong, Wendy A Teft, Justin Ly, Yung-Hsiang Chen, Bruno Alicke, Richard B Kim, Edna F Choo. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.
Breast cancer research and treatment.
2013 May; 139(1):61-9. doi:
10.1007/s10549-013-2530-1. [PMID: 23605084] - Wendy A Teft, Inna Y Gong, Brian Dingle, Kylea Potvin, Jawaid Younus, Theodore A Vandenberg, Muriel Brackstone, Francisco E Perera, Yun-Hee Choi, Guangyong Zou, Robin M Legan, Rommel G Tirona, Richard B Kim. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
Breast cancer research and treatment.
2013 May; 139(1):95-105. doi:
10.1007/s10549-013-2511-4. [PMID: 23580071] - E M E Balkenende, T Dahhan, S C Linn, N G L Jager, J H Beijnen, M Goddijn. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Human reproduction (Oxford, England).
2013 Apr; 28(4):953-9. doi:
10.1093/humrep/des445. [PMID: 23335608] - Marina Venzon Antunes, Daniela Dornelles Rosa, Tamyris Dos Santos Viana, Huander Andreolla, Tiago Ozelame Fontanive, Rafael Linden. Sensitive HPLC-PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma.
Journal of pharmaceutical and biomedical analysis.
2013 Mar; 76(?):13-20. doi:
10.1016/j.jpba.2012.12.005. [PMID: 23291438] - F L Opdam, V O Dezentje, J den Hartigh, A S Modak, R Vree, E Batman, C H Smorenburg, J W R Nortier, H Gelderblom, H-J Guchelaar. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
Cancer chemotherapy and pharmacology.
2013 Mar; 71(3):593-601. doi:
10.1007/s00280-012-2034-4. [PMID: 23228987] - Casey Lynnette Overby, Emily Beth Devine, Peter Tarczy-Hornoch, Ira J Kalet. Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions.
Journal of the American Medical Informatics Association : JAMIA.
2012 Sep; 19(5):840-50. doi:
10.1136/amiajnl-2011-000405. [PMID: 22539082] - Marzia Del Re, Angela Michelucci, Paolo Simi, Romano Danesi. Pharmacogenetics of anti-estrogen treatment of breast cancer.
Cancer treatment reviews.
2012 Aug; 38(5):442-50. doi:
10.1016/j.ctrv.2011.08.003. [PMID: 21917382] - Marina V Antunes, Rafael Linden, Tamyris V Santos, Pierre Wallemacq, Vincent Haufroid, Jean-François Classen, Huander Andreolla, Nathalia Costa, Tiago O Fontanive, Daniela D Rosa. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Therapeutic drug monitoring.
2012 Aug; 34(4):422-31. doi:
10.1097/ftd.0b013e318260b46e. [PMID: 22777153] - Jennifer Gjerde, Sara Gandini, Aliana Guerrieri-Gonzaga, Line L Haugan Moi, Valentina Aristarco, Gunnar Mellgren, Andrea Decensi, Ernst A Lien. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.
Breast cancer research and treatment.
2012 Jul; 134(2):693-700. doi:
10.1007/s10549-012-2074-9. [PMID: 22562123] - Alan H B Wu, Wendy Lorizio, Simone Tchu, Kara Lynch, Roy Gerona, Wuyang Ji, Weiming Ruan, Kathryn J Ruddy, Stephen D Desantis, Harold J Burstein, Elad Ziv. Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.
Breast cancer research and treatment.
2012 Jun; 133(2):677-83. doi:
10.1007/s10549-012-1963-2. [PMID: 22294487] - N G L Jager, H Rosing, S C Linn, J H M Schellens, J H Beijnen. Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.
Breast cancer research and treatment.
2012 Jun; 133(2):793-8. doi:
10.1007/s10549-012-2000-1. [PMID: 22388692] - M F Barginear, M Jaremko, I Peter, C Yu, Y Kasai, M Kemeny, G Raptis, R J Desnick. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
Clinical pharmacology and therapeutics.
2011 Oct; 90(4):605-11. doi:
10.1038/clpt.2011.153. [PMID: 21900890] - P Bourassa, S Dubeau, Ghulam M Maharvi, Abdul H Fauq, T J Thomas, H A Tajmir-Riahi. Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.
European journal of medicinal chemistry.
2011 Sep; 46(9):4344-53. doi:
10.1016/j.ejmech.2011.07.005. [PMID: 21777996] - William J Irvin, Christine M Walko, Karen E Weck, Joseph G Ibrahim, Wing K Chiu, E Claire Dees, Susan G Moore, Oludamilola A Olajide, Mark L Graham, Sean T Canale, Rachel E Raab, Steven W Corso, Jeffrey M Peppercorn, Steven M Anderson, Kenneth J Friedman, Evan T Ogburn, Zeruesenay Desta, David A Flockhart, Howard L McLeod, James P Evans, Lisa A Carey. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2011 Aug; 29(24):3232-9. doi:
10.1200/jco.2010.31.4427. [PMID: 21768473] - Anne-Joy M de Graan, Sebastiaan F Teunissen, Filip Y F L de Vos, Walter J Loos, Ron H N van Schaik, Felix E de Jongh, Aad I de Vos, Robbert J van Alphen, Bronno van der Holt, Jaap Verweij, Caroline Seynaeve, Jos H Beijnen, Ron H J Mathijssen. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2011 Aug; 29(24):3240-6. doi:
10.1200/jco.2010.32.9839. [PMID: 21768449] - P Bourassa, S Dubeau, Ghulam M Maharvi, Abdul H Fauq, T J Thomas, H A Tajmir-Riahi. Binding of antitumor tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen to human serum albumin.
Biochimie.
2011 Jul; 93(7):1089-101. doi:
10.1016/j.biochi.2011.03.006. [PMID: 21439346] - L Madlensky, L Natarajan, S Tchu, M Pu, J Mortimer, S W Flatt, D M Nikoloff, G Hillman, M R Fontecha, H J Lawrence, B A Parker, A H B Wu, J P Pierce. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.
Clinical pharmacology and therapeutics.
2011 May; 89(5):718-25. doi:
10.1038/clpt.2011.32. [PMID: 21430657] - Joanne S L Lim, Xiang A Chen, Onkar Singh, Yoon S Yap, Raymond C H Ng, Nan S Wong, Mabel Wong, Edmund J D Lee, Balram Chowbay. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
British journal of clinical pharmacology.
2011 May; 71(5):737-50. doi:
10.1111/j.1365-2125.2011.03905.x. [PMID: 21480951] - Enrique Ochoa Aranda, Josep Esteve-Romero, Maria Rambla-Alegre, Juan Peris-Vicente, Devasish Bose. Development of a methodology to quantify tamoxifen and endoxifen in breast cancer patients by micellar liquid chromatography and validation according to the ICH guidelines.
Talanta.
2011 Apr; 84(2):314-8. doi:
10.1016/j.talanta.2011.01.022. [PMID: 21376950] - Wendy A Teft, Sara E Mansell, Richard B Kim. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
Drug metabolism and disposition: the biological fate of chemicals.
2011 Mar; 39(3):558-62. doi:
10.1124/dmd.110.036160. [PMID: 21148080] - A Ahmad, S Shahabuddin, S Sheikh, P Kale, M Krishnappa, R C Rane, I Ahmad. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects.
Clinical pharmacology and therapeutics.
2010 Dec; 88(6):814-7. doi:
10.1038/clpt.2010.196. [PMID: 20981001] - Andrea Decensi, Chris Robertson, Aliana Guerrieri-Gonzaga, Davide Serrano, Massimiliano Cazzaniga, Serena Mora, Marcella Gulisano, Harriet Johansson, Viviana Galimberti, Enrico Cassano, Simona M Moroni, Franca Formelli, Ernst A Lien, Giuseppe Pelosi, Karen A Johnson, Bernardo Bonanni. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009 Aug; 27(23):3749-56. doi:
10.1200/jco.2008.19.3797. [PMID: 19597031] - Marcelo F Montenegro, Lisandra R Pessa, Valéria A Gomes, Zeruesenay Desta, David A Flockhart, Jose E Tanus-Santos. Assessment of vascular effects of tamoxifen and its metabolites on the rat perfused hindquarter vascular bed.
Basic & clinical pharmacology & toxicology.
2009 May; 104(5):400-7. doi:
10.1111/j.1742-7843.2009.00377.x. [PMID: 19413660] - Miriam B Buck, Janet K Coller, Thomas E Mürdter, Michel Eichelbaum, Cornelius Knabbe. TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.
Breast cancer research and treatment.
2008 Jan; 107(1):15-24. doi:
10.1007/s10549-007-9526-7. [PMID: 18043895] - J Gjerde, M Hauglid, H Breilid, S Lundgren, J E Varhaug, E R Kisanga, G Mellgren, V M Steen, E A Lien. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
Annals of oncology : official journal of the European Society for Medical Oncology.
2008 Jan; 19(1):56-61. doi:
10.1093/annonc/mdm434. [PMID: 17947222] - Young Chai Lim, Lang Li, Zeruesenay Desta, Qianqian Zhao, James M Rae, David A Flockhart, Todd C Skaar. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
The Journal of pharmacology and experimental therapeutics.
2006 Aug; 318(2):503-12. doi:
10.1124/jpet.105.100511. [PMID: 16690721] - Young Chai Lim, Zeruesenay Desta, David A Flockhart, Todd C Skaar. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Cancer chemotherapy and pharmacology.
2005 May; 55(5):471-8. doi:
10.1007/s00280-004-0926-7. [PMID: 15685451] - Michael D Johnson, Hong Zuo, Kyung-Hoon Lee, Joseph P Trebley, James Michael Rae, Ross V Weatherman, Zeruesanay Desta, David A Flockhart, Todd C Skaar. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
Breast cancer research and treatment.
2004 May; 85(2):151-9. doi:
10.1023/b:brea.0000025406.31193.e8. [PMID: 15111773] - Vered Stearns, Michael D Johnson, James M Rae, Alan Morocho, Antonella Novielli, Pankaj Bhargava, Daniel F Hayes, Zeruesenay Desta, David A Flockhart. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Journal of the National Cancer Institute.
2003 Dec; 95(23):1758-64. doi:
10.1093/jnci/djg108. [PMID: 14652237] - E A Lien, E Solheim, O A Lea, S Lundgren, S Kvinnsland, P M Ueland. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.
Cancer research.
1989 Apr; 49(8):2175-83. doi:
. [PMID: 2702659] - E A Lien, E Solheim, S Kvinnsland, P M Ueland. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile.
Cancer research.
1988 Apr; 48(8):2304-8. doi:
. [PMID: 3349495]